March 29, 2019
Ono Pharmaceutical said on March 28 that it has filed an application in Japan seeking an additional indication for its anti-PD-1 antibody Opdivo (nivolumab) for the treatment of microsatellite instability high (MSI-H) unresectable advanced or recurrent colorectal cancer. The submission...read more